细胞周期素D1、Ki67在鼻咽癌中的表达及意义(英文)

目的检测 cyclinD1及 Ki67在鼻咽癌中的表达,探讨其与鼻咽癌的生物学行为及预后的关系。方法收集我院1996年鼻咽癌放疗前活检组织石蜡标本56例,应用 cyclinD1及 Ki67单克隆抗体进行 SP 法免疫组化染色,并对患者进行定期随访,统计分析其生物学行为及预后。结果 cyclinD1阳性表达范围为0%～54%,其中30例(53.6%)高表达;26例(46.4%)低表达。Ki67阳性表达范围为0%～31%,其中16例(28.6%)高表达(HPI);40例(71.4%)低表达(LPI)。cyclinD1低表达或 Ki67高表达者,对射线敏感,预后较好;反之,cyclinD1高表达或 Ki67低表达者对射线较为抗拒,预后较差。结论 cyclinD1、Ki67可分别作为评估鼻咽癌患者放射敏感性和预后的独立指标,并为患者的个体化治疗提供了理论依据。     

Ki67在鼻咽癌中的表达及意义

 目的　观察Ki6 7在鼻咽癌中的表达及其与鼻咽癌生物学行为和预后的关系。方法　应用SP免疫组化染色法检测鼻咽癌患者放疗前活检组织石蜡标本中Ki6 7在鼻咽癌中的表达情况。结果　 5 6例鼻咽癌标本中 ,Ki6 7阳性表达范围为 0～ 31% ,其中高表达者 16例 ,低表达者 4 0例 (含 14例阴性 )。Ki6 7高表达者 ,对射线敏感 ,预后较好 ;反之 ,对射线不敏感 ,预后较差。结论　Ki6 7可作为评估鼻咽癌患者放射敏感性、预测预后的独立指标之一。     

cyclinD1、p27和ki-67在鼻咽鳞癌组织中的表达及意义

目的:探讨cyclinD1、p27和ki-67在鼻咽鳞癌组织中的表达及意义.方法:用免疫组化SP法检测cyclinD1、p27和ki-67在60例不同分化级别的鼻咽鳞癌组织及20例炎症组织中的表达.结果:cyclinD1、p27和ki-67在炎症及鳞癌组织中表达的差异有统计学意义;在鳞癌中,p27与cyclinD1、ki-67的异常表达与肿瘤组织学分级,临床分期相关(P＜0.05),与淋巴结转移无关(P＞0.05);p27表达与ki67及cyclinD1表达呈负相关,cyclinD1表达与ki-67表达呈正相关.结论:cyclinD1、p27及ki-67的检测可作为预测肿瘤预后及反应肿瘤恶性程度的参考指标.     

细胞周期素D1、Ki—67与鼻咽癌

细胞周期素D1（CyclinD1)是细胞周期G1期的重要调控因子之一，它在多种癌组织中扩增和过表达，Ki-67是一种细胞增殖核抗原，广泛应用于评估肿瘤细胞持增殖活性。多数学者认为二者的表达高低与肿瘤的组织类型、分化程度及预后有关，可根据二者的表达情况选择不同的治疗手段、预测放射敏感性及改善预后，但也有学者持相反的观点，本文主要综述二者与鼻咽癌的关系及意义。     

VEGF-C与鼻咽癌增殖和转移的关系

目的 检测血管内皮生长因子C（VEGF-C）在鼻咽癌（NPC）组织中的表达,探讨其与鼻咽癌细胞增殖和转移的关系。方法NPC患者放疗前的活检组织标本62例,将每例标本均分2份,一份应用VEGF-C多克隆抗体进行SP法免疫组化染色,另一份应用流式细胞术以Ki67抗体检测其增殖状况。放疗后定期随访患者,统计分析其3年生存率及死亡原因。结果62例NPC标本中,VEGF-C表达范围为0～82％,其中阴性（-）17例（27．4％）,弱阳性（＋）13例（21．0％）,中等阳性（＋＋）18例（29．0％）,强阳性（＋＋＋）14例（22．6％）。Ki67表达范围为0-52％,其中低表达（LPI）者40例（64．5％,含15例阴性）,高表达（HPI）者22例（35．5％）。VEGF-C与Ki67表达之间存在明显的正相关（r=0．323,P〈0．05）。3年生存率为66．1％。有淋巴结转移者的VEGF-C表达显著强于无淋巴结转移者（P〈0．01）。8例死于远处转移的患者中,VEGF-C表达均为强阳性;21例无病生存者中,VEGF-C表达为（-）或（＋）者占80．9％。VEGF-C表达与患者预后存在一定的负相关,但差异无统计学意义（r=-0．219,P〉0．05）。结论VEGF-C高表达与鼻咽癌细胞的增殖和转移能力相关,但不是影响患者预后的独立因素,而是一个预测无病生存期长短的指标。     

P53蛋白、血管内皮生长因子等生物分子指标与鼻咽癌放射敏感性的关系

背景与目的:临床上常见鼻咽癌患者虽属于同一分期,并采用相同的治疗技术和治疗剂量,却有20%～40%患者在5年内出现射野内复发,这主要与肿瘤细胞的放射治疗内在敏感性个体差异有关。本研究对鼻咽癌细胞增殖、凋亡以及肿瘤血管生成、淋巴管生成等状况与放疗敏感性的关系作一初步探讨。方法:对放疗敏感及放疗抗拒的鼻咽癌患者活检标本各60例行免疫组化法检测P53、血管内皮生长因子(vascularendothelialgrowthfactor,VEGF)、Survivin、VEGF-C、Ki67蛋白及微血管密度(microvasculardensity,MVD)表达,结合临床资料,分析它们之间的相关性。结果:P53、VEGF、Survivin、VEGF-C、Ki67蛋白阳性率分别为65.0%、57.5%、60.8%、42.5%、57.5%,放射敏感组及放射抗拒组P53、VEGF、MVD表达分别为(25.97±21.26)%、(18.50±19.86)%、32.65±19.61及(37.85±28.67)%、(30.83±23.94)%、41.95±16.97,两组间差异有显著性(P<0.05),Survivin、VEGF-C、Ki67蛋白阳性率两组间差异无显著性(P>0.05)。P53、VEGF、MVD三者间显著相关。结论:P53、VEGF蛋白及MVD在放疗抗拒组比放疗敏感组明显增高,有可能作为放疗前评估鼻咽癌内在放射敏感性的指标。     

Cyclin D1及PCNA与鼻咽癌放射敏感性相关性研究

[目的]探讨鼻咽癌的细胞周期素(cyclin)D1和增殖细胞核抗原(PCNA)表达与放射敏感性的关系。[方法]65例初治行放疗的鼻咽癌患者,免疫组化测定治疗前活检标本的cyclinD1和PC鄄NA表达,并与放射敏感性(放疗后的近期疗效)进行单因素和多因素的分析研究。[结果]cyclinD1阳性表达率为60%,PCNA表达率为52.3%。放射敏感者(CR)40例(61.5%),放射低敏者(PR和MR)25例(38.5%)。cyclinD1阳性表达和PCNA高表达的CR率分别为74.4%和82.4%,明显高于阴性表达及低表达者(CR率分别为42.3%和38.7%)(P<0.01)。各期中cyclinD1阳性与阴性表达及PCNA高与低表达者疗效为CR的差异有显著性(P<0.01)。Logistic多因素回归分析显示明显影响放疗效果的因素依次为:PCNA,临床分期,原发肿瘤大小,病人年龄和性别。[结论]cyclinD1阳性表达及PCNA高表达的鼻咽癌放射敏感性高,在作为预测放疗敏感性的指标上,PCNA可能较cyclinD1更有意义,为个体化的治疗方案增添了重要参考价值的生物学指标。     

Imunoexpression of Ki-67 and p53 in Rectal Cancer Tissue After Treatment with Neoadjuvant Chemoradiation

Introduction

Adjuvant or neoadjuvant chemoradiotherapy (CRT) increases the survival rates significantly, but it also increases morbidity. Molecular markers may help on prognosis evaluation and treatment choice.

Aim

The purpose of this study is to evaluate the imunoexpression of p53 and Ki-67 in rectal cancer tissue after CRT treatment.

Patients and Methods

Stage II or III rectal cancer patients were evaluated and treated with RT and 5-FU preoperatively (neoadjuvant treatment, NG) or after surgical resection of the cancer (adjuvant treatment, AG).

Results

Thirty-one patients were enrolled in the NG and 30 in the AG; 63.95% were between 50 and 70 years, 50.8% were male, and 53% were in stage III. Of the tumors, 64.5% of the NG and 63.34% of the AG had not overexpressed p53 (p?=?0.865) and 9.67% of NG and 33.33% of the AG tumors had a high proliferative index (HPI) of Ki67, p?=?0.052. We have not found any difference among metastasis development in the groups (p?=?0.708). After 5 years, patients with low proliferative index (LPI) of Ki67 tumors had the best survival rate (p?=?0.041). Patients with positive or negative p53 tumors had similar survival (p?=?0.35). Patients with HPI of Ki67 had an increased marginal risk for death (p?=?0.069).

Conclusion

The rate of tumors that overexpressed p53 was similar in both groups. Patients with p53 positive tumors survived as long as those with p53 negative. Patients treated with chemoradiotherapy before surgical resection, expressed Ki67 in a small percentage. Rectal cancer patients with LPI of Ki67 had the best prognosis.     

Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease

Background

The Ki67-LI is a valid surrogate for biologic behavior of neuroendocrine tumors (NETs), with higher levels associated with aggressive behavior. The World Health Organization (WHO) classifies NETs according to Ki67-LI (G1: <3%; G2 : 3–20%; G3: >20%). Little is known about the evolution of NETs histologic characteristics over the disease course. We sought to evaluate variations in Ki67-LI throughout NETs disease course.

Methods

We retrospectively reviewed the Sunnybrook Odette Cancer Center NET database for patients with multiple pathology specimens. Primary outcome was the WHO NET class based on Ki67-LI for each specimen. We assessed change in WHO class between specimens.

Results

Forty-three patients were retrieved, of which 39 had specimens from the primary tumor and a metastatic focus, and 4 had specimens from multiple metastatic foci. Sixteen (37.0%) were identified with Ki67-LI falling in different WHO classes on distinct biopsies. For 12 (75.0%) of those 16 patients, Ki67-LI showed enough variability for WHO class to be upstaged: 5 (31%) from G1 to G2, 2 (13%) from G2 to G3, and 5 (31%) from G1 to G3.

Conclusion

When multiple pathology specimens were available, Ki67-LI varied throughout NETs disease course, with a majority of cases upgraded to a higher WHO class. If confirmed, this finding may have implications in how neuroendocrine tumors are monitored and treated. Further research is warranted to confirm these findings, understand better the underlying mechanisms of Ki67 variability, and define its relationship to prognosis.